Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to -$16.4 million.

  • Avalo Therapeutics' Free Cash Flow fell 4197.1% to -$16.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$52.3 million, marking a year-over-year decrease of 4220.46%. This contributed to the annual value of -$49.1 million for FY2024, which is 5921.91% down from last year.
  • Latest data reveals that Avalo Therapeutics reported Free Cash Flow of -$16.4 million as of Q3 2025, which was down 4197.1% from -$11.3 million recorded in Q2 2025.
  • Avalo Therapeutics' Free Cash Flow's 5-year high stood at $5.7 million during Q3 2022, with a 5-year trough of -$19.2 million in Q2 2021.
  • Moreover, its 5-year median value for Free Cash Flow was -$11.5 million (2024), whereas its average is -$11.3 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first soared by 13473.83% in 2022, then plummeted by 44548.08% in 2024.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Free Cash Flow stood at -$17.1 million in 2021, then surged by 76.97% to -$3.9 million in 2022, then increased by 29.8% to -$2.8 million in 2023, then crashed by 445.48% to -$15.1 million in 2024, then dropped by 8.46% to -$16.4 million in 2025.
  • Its last three reported values are -$16.4 million in Q3 2025, -$11.3 million for Q2 2025, and -$9.5 million during Q1 2025.